Chen Xiaoting, Zhao Wen, Yu Hejiang, Wang Shuang, Wang Chengjun, Song Yanan, Meng Xue, Li Jisheng
Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Front Oncol. 2024 Oct 3;14:1391349. doi: 10.3389/fonc.2024.1391349. eCollection 2024.
Lung squamous cell carcinoma (LUSC) is the second most common pathological type of non-small cell lung cancer (NSCLC). However, compared with lung adenocarcinoma (LUAD), the incidence of driver gene mutations in LUSC is relatively lower and treatment options for LUSC patients are very limited. We described a LUSC patient with a novel FGFR3-IER5L fusion revealed by next generation sequencing in this report. The patient refused surgery, radiotherapy or chemotherapy and received anlotinib treatment. Anlotinib is a small molecular multi-target tyrosine kinase inhibitor, which can inhibit the activity of kinases including vascular endothelial growth factor receptor 2/3 (VEGFR2/3), fibroblast growth factor receptor 1-4 (FGFR1-4), platelet-derived growth factor receptor α/β (PDGFRα/β), and c-Kit. The patient achieved partial response and the progression-free survival was 3.8 months.
肺鳞状细胞癌（LUSC）是非小细胞肺癌（NSCLC）中第二常见的病理类型。然而，与肺腺癌（LUAD）相比，LUSC中驱动基因突变的发生率相对较低，且LUSC患者的治疗选择非常有限。在本报告中，我们描述了一名通过二代测序发现存在新型FGFR3-IER5L融合的LUSC患者。该患者拒绝手术、放疗或化疗，接受了安罗替尼治疗。安罗替尼是一种小分子多靶点酪氨酸激酶抑制剂，可抑制包括血管内皮生长因子受体2/3（VEGFR2/3）、成纤维细胞生长因子受体1-4（FGFR1-4）、血小板衍生生长因子受体α/β（PDGFRα/β）和c-Kit在内的激酶活性。该患者获得了部分缓解，无进展生存期为3.8个月。
